FDA head suspects economic motives behind tainted heparin

04/15/2008 | Wall Street Journal (free content), The · Bloomberg11

FDA Commissioner Andrew von Eschenbach told a Senate Appropriations subcommittee that the agency believes batches of Baxter International's blood thinner heparin may have been contaminated "by virtue of economic fraud." After the hearing, however, von Eschenbach told reporters that the agency had no proof the contamination was committed on purpose.

View Full Article in:

Wall Street Journal (free content), The · Bloomberg11

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Abbott
Chicago, IL
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC